File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3390/diagnostics10110918
- Scopus: eid_2-s2.0-85106420844
- PMID: 33182278
- WOS: WOS:000592762100001
Supplementary
- Citations:
- Appears in Collections:
Article: Prevalence and Impact of Reported Drug Allergies among Rheumatology Patients
Title | Prevalence and Impact of Reported Drug Allergies among Rheumatology Patients |
---|---|
Authors | |
Keywords | allergy drug hypersensitivity prevalence rheumatology |
Issue Date | 2020 |
Publisher | MDPI AG. The Journal's web site is located at http://www.mdpi.com/journal/diagnostics |
Citation | Diagnostics, 2020, v. 10 n. 11, p. article no. 918 How to Cite? |
Abstract | Background: Drug allergies (DA) are immunologically mediated adverse drug reactions and their manifestations depend on a variety of drug- and patient-specific factors. The dysregulated immune system underpinning rheumatological diseases may also lead to an increase in hypersensitivity reactions, including DA. The higher prevalence of reported DA, especially anti-microbials, also restricts the medication repertoire for these already immunocompromised patients. However, few studies have examined the prevalence and impact of reported DA in this group of patients. Methods: Patients with a diagnosis of rheumatoid arthritis (RA), spondyloarthritis (SpA), or systemic lupus erythematosus (SLE) were recruited from the rheumatology clinics in a tertiary referral hospital between 2018 and 2019. Prevalence and clinical outcomes of reported DA among different rheumatological diseases were calculated and compared to a cohort of hospitalized non-rheumatology patients within the same period. Results: A total of 6081 patients (2541 rheumatology patients: 1286 RA, 759 SpA, and 496 SLE; and 3540 controls) were included. DA was more frequently reported among rheumatology patients compared to controls (23.8% vs. 13.8%, p < 0.01). Antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs) were the two most commonly reported categories of DA with a prevalence of 12.0% and 5.1%, respectively. Reported antibiotics allergies were more frequent in patients with RA (OR = 1.20, 95% CI = 1.02–1.62, p = 0.03) and SLE (OR = 4.69, 95% CI = 3.69–5.95, p < 0.01); and associated with increased infection-related admissions among rheumatology patients (OR = 1.79, 95% CI = 1.09–2.95, p = 0.02). Among the subgroup of patients referred for allergy testing, 85.7% of beta-lactam antibiotic allergy labels were found to be inaccurate and de-labelled after negative drug provocation testing. Conclusion: The prevalence of reported DA was significantly higher in rheumatology patients. Reported antibiotic allergy was associated with increased rate of infection-related admissions. However, the rate of genuine antibiotic allergy was low. Further studies are needed to guide proper assessment of reported DA and impact of comprehensive allergy testing in this group of patients. |
Persistent Identifier | http://hdl.handle.net/10722/294096 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chan, SCW | - |
dc.contributor.author | Yeung, WWY | - |
dc.contributor.author | Wong, JCY | - |
dc.contributor.author | Chui, ESH | - |
dc.contributor.author | Lee, MSH | - |
dc.contributor.author | Chung, HY | - |
dc.contributor.author | Cheung, TT | - |
dc.contributor.author | Lau, CS | - |
dc.contributor.author | Li, PH | - |
dc.date.accessioned | 2020-11-23T08:26:16Z | - |
dc.date.available | 2020-11-23T08:26:16Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Diagnostics, 2020, v. 10 n. 11, p. article no. 918 | - |
dc.identifier.uri | http://hdl.handle.net/10722/294096 | - |
dc.description.abstract | Background: Drug allergies (DA) are immunologically mediated adverse drug reactions and their manifestations depend on a variety of drug- and patient-specific factors. The dysregulated immune system underpinning rheumatological diseases may also lead to an increase in hypersensitivity reactions, including DA. The higher prevalence of reported DA, especially anti-microbials, also restricts the medication repertoire for these already immunocompromised patients. However, few studies have examined the prevalence and impact of reported DA in this group of patients. Methods: Patients with a diagnosis of rheumatoid arthritis (RA), spondyloarthritis (SpA), or systemic lupus erythematosus (SLE) were recruited from the rheumatology clinics in a tertiary referral hospital between 2018 and 2019. Prevalence and clinical outcomes of reported DA among different rheumatological diseases were calculated and compared to a cohort of hospitalized non-rheumatology patients within the same period. Results: A total of 6081 patients (2541 rheumatology patients: 1286 RA, 759 SpA, and 496 SLE; and 3540 controls) were included. DA was more frequently reported among rheumatology patients compared to controls (23.8% vs. 13.8%, p < 0.01). Antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs) were the two most commonly reported categories of DA with a prevalence of 12.0% and 5.1%, respectively. Reported antibiotics allergies were more frequent in patients with RA (OR = 1.20, 95% CI = 1.02–1.62, p = 0.03) and SLE (OR = 4.69, 95% CI = 3.69–5.95, p < 0.01); and associated with increased infection-related admissions among rheumatology patients (OR = 1.79, 95% CI = 1.09–2.95, p = 0.02). Among the subgroup of patients referred for allergy testing, 85.7% of beta-lactam antibiotic allergy labels were found to be inaccurate and de-labelled after negative drug provocation testing. Conclusion: The prevalence of reported DA was significantly higher in rheumatology patients. Reported antibiotic allergy was associated with increased rate of infection-related admissions. However, the rate of genuine antibiotic allergy was low. Further studies are needed to guide proper assessment of reported DA and impact of comprehensive allergy testing in this group of patients. | - |
dc.language | eng | - |
dc.publisher | MDPI AG. The Journal's web site is located at http://www.mdpi.com/journal/diagnostics | - |
dc.relation.ispartof | Diagnostics | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | allergy | - |
dc.subject | drug | - |
dc.subject | hypersensitivity | - |
dc.subject | prevalence | - |
dc.subject | rheumatology | - |
dc.title | Prevalence and Impact of Reported Drug Allergies among Rheumatology Patients | - |
dc.type | Article | - |
dc.identifier.email | Chung, HY: jameschy@hku.hk | - |
dc.identifier.email | Cheung, TT: tcheungt@hku.hk | - |
dc.identifier.email | Lau, CS: cslau@hku.hk | - |
dc.identifier.email | Li, PH: liphilip@hku.hk | - |
dc.identifier.authority | Chung, HY=rp02330 | - |
dc.identifier.authority | Cheung, TT=rp01682 | - |
dc.identifier.authority | Lau, CS=rp01348 | - |
dc.identifier.authority | Li, PH=rp02669 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3390/diagnostics10110918 | - |
dc.identifier.pmid | 33182278 | - |
dc.identifier.pmcid | PMC7695245 | - |
dc.identifier.scopus | eid_2-s2.0-85106420844 | - |
dc.identifier.hkuros | 318768 | - |
dc.identifier.volume | 10 | - |
dc.identifier.issue | 11 | - |
dc.identifier.spage | article no. 918 | - |
dc.identifier.epage | article no. 918 | - |
dc.identifier.eissn | 2075-4418 | - |
dc.identifier.isi | WOS:000592762100001 | - |
dc.publisher.place | Switzerland | - |
dc.identifier.issnl | 2075-4418 | - |